Year Founded
2018
Ownership
Private
Employees
~10
Therapeutic Areas
OncologyNeurologyImmunologyInfectious DiseasesDermatology
Stage
Phase 2
Modalities
Small molecule

CytoAgents General Information

Successfully completed Phase 1 trials and currently conducting Phase 1b/2a trial for CTO1681 in CAR T-cell therapy-induced CRS. Trial is enrolling approximately 54 patients with diffuse large B-cell lymphoma.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Pittsburgh, Pennsylvania
United States

Drug Pipeline

CTO1681
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to CytoAgents's pipeline data

Book a demo

Key Partnerships

UPMC Hillman Cancer Center

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

CytoAgents Funding

Deal TypeDateAmountStatusStage
Later Stage VCSep 25, 2024$2.0MCompletedPhase 2
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view CytoAgents's complete valuation and funding history, request access »

CytoAgents Investors

Innovation Works
Investor Type: Venture Capital
Holding: Minority